RxDoctor Payments Data

Nathan Tracey, DO

Family Medicine · Albuquerque, NMNPI 1770873531

Payments from drug & device makers

$1,646in general payments, 2019–2025

Across 54 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$923
  • Amgen$138
  • Sanofi-aventis U.S. LLC$110
  • Lilly USA, LLC$100
  • Boehringer Ingelheim$89
  • Novo Nordisk$48
  • plus $238 from 8 others

What the payments were for

  • Travel & lodging$47129%
  • Food & beverage$1,12869%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,646 in reported general payments places this provider in the 85th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$41,093
Medicare patients
242
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$53,029
MounjaroTirzepatide43$44,508
EliquisApixaban27$41,536
JardianceEmpagliflozin11$16,028
Dexlansoprazole DrDexlansoprazole12$3,509
Fenofibrate19$3,343
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,512
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,188
Esomeprazole Magnesium12$2,133
Gabapentin41$1,947
Levothyroxine Sodium169$1,862
Pantoprazole Sodium80$1,447
SynthroidLevothyroxine Sodium18$1,281
Losartan Potassium129$1,238
Tamsulosin Hcl63$1,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$48$53,02949 claims
Lilly USA, LLCMounjaro$100$44,50843 claims
PfizerEliquis$29$41,53627 claims
Boehringer IngelheimJardiance$89$16,02811 claims
AbbVieSynthroid$44$1,28118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →